December 18, 2017
A preclinical study from Belgium has shown promising results with the PET tracer florbetapir for targeting amyloid plaque and tau tangles in the brain and potentially evaluating the efficacy of certain Alzheimer's treatments. Findings were published in the December issue of The Journal of Nuclear Medicine.
...Using the PET tracers florbetapir (Amyvid, Eli Lilly), FDG, and PBR111, the researchers compared a group of normal control mice with mice genetically altered to have Alzheimer's.
...All three tracers detected pathological differences between the genetically modified mice and the controls; however, only florbetapir illustrated the effects of inhibitor treatment by identifying reduced beta-amyloid pathology in the genetically modified mice, as confirmed by the microscopic studies.